| Title |
Ability of PITX2 methylation to predict survival in patients with prostate cancer
|
|---|---|
| Published in |
OncoTargets and therapy, November 2015
|
| DOI | 10.2147/ott.s83914 |
| Pubmed ID | |
| Authors |
Jiu-zhi Li, Yu Zhang, Bin Wen, Ming Li, Yu-jie Wang |
| Abstract |
The aim of this study was to explore whether candidate gene methylation can effectively predict death from prostate cancer. After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels. The case group comprised 45 patients with a Gleason score ≤7 who had died as a result of prostate cancer, and the control group comprised 90 current prostate cancer patients or those who died of other causes. The methylation possibility of each of the candidate genes were maximized. Univariate conditional logistic was applied for data analysis and to evaluate prediction efficiency of gene methylation on prostate cancer. The results indicated that a raised level of PITX2 methylation increased the likelihood of death due to prostate cancer by 10% (odds ratio 1.56, 95% confidence interval 1.17-2.08; P=0.005). Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer. Methylation of PITX2 is an effective biomarker to predict death from prostate cancer, particularly in patients with a low Gleason score. |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 12 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 42% |
| Other | 1 | 8% |
| Student > Bachelor | 1 | 8% |
| Student > Doctoral Student | 1 | 8% |
| Student > Ph. D. Student | 1 | 8% |
| Other | 1 | 8% |
| Unknown | 2 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 33% |
| Agricultural and Biological Sciences | 2 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
| Business, Management and Accounting | 1 | 8% |
| Medicine and Dentistry | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 3 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2016.
All research outputs
#16,737,737
of 25,394,764 outputs
Outputs from OncoTargets and therapy
#986
of 3,016 outputs
Outputs of similar age
#167,142
of 294,905 outputs
Outputs of similar age from OncoTargets and therapy
#25
of 104 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,905 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 104 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.